Calidi Biotherapeutics Inc (CLDI) Stock Short-term Performance Analysis

Currently, Calidi Biotherapeutics Inc [CLDI] is trading at $0.76, down -23.85%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CLDI shares have gain 209.19% over the last week, with a monthly amount glided 136.10%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Calidi Biotherapeutics Inc [AMEX: CLDI] stock has seen the most recent analyst activity on November 22, 2023, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $11. Previously, Robert W. Baird started tracking the stock with Outperform rating on October 09, 2023, and set its price target to $9.

This stock has fluctuated between a low of $0.20 and a high of $3.89 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $5.5 within the next 12 months. Calidi Biotherapeutics Inc [AMEX: CLDI] shares were valued at $0.76 at the most recent close of the market. An investor can expect a potential return of 623.68% based on the average CLDI price forecast.

Analyzing the CLDI fundamentals

To continue investigating profitability, this company’s Return on Assets is posted at -1.43, Equity is 6.36 and Total Capital is -2.08. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.59.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6550 points at the first support level, and at 0.5500 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9100, and for the 2nd resistance point, it is at 1.0600.

Ratios To Look Out For

To put it in perspective, the Current Ratio for Calidi Biotherapeutics Inc [AMEX:CLDI] is 2.12. As well, the Quick Ratio is 2.12, while the Cash Ratio is 1.95.